a biotechnology company focused on gastrointestinal diseases that was acquired by Merck for $10.8 billion in 2023. Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today. Read More: Earn up ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

However, this does not break the investment thesis on AbbVie as the company is diversified enough to carry on and continue to deliver long-term shareholder value. So, what went wrong with emraclidine?